Corporate News tagged:
Clinical Capabilities (2)
May 24, 2021
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
The administrations of Stemchymal have been completed to all enrolled patients in phase II clinical trial for the treatment of SCA in Japan.
May 18, 2021
VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL
Read more about how REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Apr 19, 2021
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
Read about REPROCELL Bioserve's launch of new clinical oncology diagnostic services featuring NGS-based genomic profiling, targeting a wide range of cancers
Apr 08, 2021
Launch of New Testing Service of Identification for Covid-19 Variants
REPROCELL has launched a new testing service of identification for Covid-19 variants using Allplex SARS-CoV-2 Variants I Assay manufactured by Seegene Inc.
Mar 22, 2021
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
Find out more about REPROCELL's collaboration with Blacktrace Holdings Ltd in the domestic sales of their Nadia series: a single-cell analytical system.
Mar 17, 2021
REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
We are pleased to announce that the REPROCELL Regenerative Medicine Center has been certified as a manufacturing facility for cell culture products.
Mar 11, 2021
Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India
Read Bioserve Biotechnologies announcement about it's new, non invasive prenatal testing service. Providing Preimplantation Genetic Screening and Diagnosis
Mar 01, 2021
REPROCELL launches PCR Testing Service for COVID-19
Read REPROCELL's announcement that it will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc.
Feb 25, 2021
REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
Read about the phase II clinical trial of Stemchymal, where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with SCA.
Dec 17, 2020
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
Find out more about REPROCELL's announcement that they will launch a new service to generate individual specific induced pluripotent stem cells (iPSC's)
Aug 17, 2020
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Jul 15, 2020
REPROCELL’s Personal iPS Service is Launched in Japan
Read more about REPROCELL's exciting new launch of its Personal iPS service, allowing customers to store cells for future regenerative medicine treatment.
Feb 28, 2020
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
REPROCELL is pleased to announce that the first patient has been registered and been administrated at for the Phase II clinical trial of Stemchyma.
Aug 01, 2018
Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
Read the Japan Pharmaceuticals and Medical Device Agency's announcement that REPROCELL has acheived PMDA Approval of CTN for Phase II Trial of Stemchymal
Nov 22, 2016
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
REPROCELL announces an entrustment contract with Healios K.K. for sample testing support of human clinical trials conducted by Healios.
Nov 11, 2016
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.